Zoetis CEO: It's unclear if animal health will be a part of pharmaceutical tariffs

Welcome back. This morning we got second quarter results from Zoetas which showed the company beating estimates raising its guidance. The stock did close lower on weakness from Labrella.This is its osteoarthritis medication for dogs. But joining us now on set for an exclusive interview is Zoetta CEO Kristen Pat. Kristen, it's great to have you on.And it was it was a beat and raised quarter and yet shares were under pressure. I guess just walk me through what you're seeing with Labrella as that seems to be w ...